Dermata Therapeutics, Inc.

NASDAQ: DRMA · Healthcare · Biotechnology

PublicHQ San Diego, CA · San DiegoCIK 0001853816Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 36DQ —GM —SS 24

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$7.6M

Employees

as of 2026-09-25

Market cap

$797.4k

as of 2026-09-25

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$7.6M-$7.6M2025

Operating income-$7.8M-$7.8M2025

Total assets$7.9M$7.9M2025

Liabilities$1.6M$1.6M2025

Equity$6.2M$6.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Dermata Therapeutics, Inc.’s financial profile?

Dermata Therapeutics, Inc. earned -$7.6M in FY2025 net income.

Peers · Healthcare

RushNet, Inc.——Ocean Biomedical, Inc.——ZyVersa Therapeutics, Inc.——Stella Diagnostics Inc.——Nascent Pharma Holdings, Inc.——Halberd Corporation——

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B61C Sempra$12.4B63C DexCom, Inc.$4.7B87A ResMed Inc.$5.1B——Illumina, Inc.$4.3B84B+

Key facts

CEOGerald T. Proehl

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Diego, CA

ExchangeNASDAQ: DRMA

Employees9

IPO date2021-08-13

Latest filings

8-K2026-08-17 10-Q2026-08-11 8-K2026-08-11 8-K2026-08-05 8-K2026-05-27 8-K2026-05-13 10-Q2026-05-13 DEF 14A2026-04-17

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.